PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450



_	٠	
ς.	1	•
•)	ı	

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: MO1375 US CNT 4 INVENTORS: James R. McCarthy; Michael L.

Edwards; Donald P. Matthews

TITLE: NOVEL 2'-HALOMETHYLIDENE, 2'-ETHENYLIDENE AND 2'-ETHYNYL CYTIDINE, URIDINE AND GUANOSINE DERIVATIVES I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231,

18 September 2003

Date of Deposit

Signature

Light Control of the Control of th

Express Mail No.

APPLICATION ELEMENTS

AFF	LICA	TION ELEMENTS					
1.		*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)					
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	58			
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets				
4.	Oath a.	or Declaration Newly executed (original or copy)	Total Pages	1			
b. Copy from a prior application (37 CFR § 1.63(d)) (for continuation/divisional with Box 16 completed)							
		i. DELETION OF INVENTOR(S) Signed statement attached deleting i application, see 37 CFR §§ 1.63(d)(2)	nventor(s) nan 2) and 1.33(b).	ned in the prior			
5.		Microfiche Computer Program (Appendix)					
6.	Nucleotide and/or Amino Acid Sequence Submission						

Page 2 (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) C. Statement verifying identity of above copies If a CONTINUING Application, check appropriate box, and supply the requisite information: Divisional Continuation-in-part of prior application no: 10/164,848, filed June 6, 2002, Examiner Crane, Group/Art Unit 1623. (The cross reference has been/will be inserted on page one of the specification). This application claims the benefit of U.S. Provisional Application No. filed . (The cross reference has been/will be inserted on page one of the specification). Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. **ACCOMPANYING APPLICATION PARTS** 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement Power of (when there is an assignee) Attorney English Translation Document (if applicable) 9. 10. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 11. **Preliminary Amendment** 12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 13. *Small Entity Statement(s) Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired 14. Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. Other: E-PAVE; Copy of Declaration; Copy of Extension of Time MO1375USCNT 3 CORRESPONDENCE ADDRESS 005487 Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) Mark C. Nelligan, Reg. No. 36,389

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-2388 Telefax (908) 231-2626 Aventis Docket No. MO 1375 US CNT 4

Application Transmittal Letter

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 750.00

Complete if Known				
Application Number	NOT YET ASSIGNED			
Filing Date	FILED HEREWITH			
First Named Inventor	James R. McCarthy et al			
Examiner Name	Lawrence E. Crane			
Group / Art Unit	1623			
Attorney Docket No.	MO1375 LIS CNT 4			

METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)							
Check Credit Card Money Other None	3. ADDITIONAL FEES						
Deposit Account	Large E		Small E	ntity Fee			
Deposit Account Number	Fee Code	Fee (\$)	Code	(\$)	Fee Description	Fee Paid	
Deposit Account Aventis Pharmaceuticals Inc.	1051	420	2051	e.e.	Cyrobaras lata filipa for aventh		
The Commissioner is authorized to: (check all that apply)		130		65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or		
Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25	cover sheet		
Charge any additional fee(s) during the pendency of this application	1053 1812	130 2,520	1053 1812	130 2,520	Non-English Specification For filing a request for reexamination		
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action		
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month		
Large Entity Small Entity Fee	4050	440	2252	205	Extension for rophywithin assend as-at-		
Fee Fee Fee Fee Fee Description Paid Code (\$) Code (\$)	1252	410	2252	205	Extension for reply within second month		
1001 750 2001 375 Utility filing fee 750	1253	930	2253	465	Extension for reply within third month		
1002 330 2002 165 Design filing Fee	1254	1,450	2254	725	Extension for reply within fourth month		
1003 520 2003 260 Plant filing fee	1255	1970	2255	985	Extension for reply within fifth month		
1004 750 2004 375 Reissue filing fee	1401	320	2401	160	Notice of Appeal		
1005 160 2005 80 Provisional filing fee	1402	320	2402	160	Filing a brief in support of an appeal		
CURTOTAL (4) (C)\$750.00	1403	280	2403	140	Request for oral hearing		
SUBTOTAL (1) (\$)\$750.00							
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding		
Fee Extra from Fee Claims below Paid	1452	110	2452	55	Petition to revive - unavoidable		
Total Claims 1 -20**= 0 x 18 = 00.00	1453	1,300	2453	650	Petition to revive - unintentional		
Independent 1 - 3**= 0 x 84 = 00.00	1501	1,300	2501	650	Utility issue fee (or reissue)		
Claims	1502	470	2502	235	Design issue fee		
Multiple Dependent =	1503	630	2503	315	Plant issue fee		
	1460	130	1460	130	Petitions to the Commissioner		
Large Entity Small Entity	1807	50	1807	50	Petitions related to provisional applications		
Fee Fee Fee Code (\$) Fee Description	i				аррікавона		
1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure Stmt		
1201 84 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)		
1203 280 2203 140 Multiple dependent claim, if not paid	1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))		
1204 84 2204 42 **Reissue independent claims over original patent	1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))		
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	750	2801	375	Request for Continued Examination (RCE)		
	1802	900	1802	900	Request for expedited examination of a design application		
SUBTOTAL (2) (\$)750.00	Other fee	e (specify)					
**or number previously paid, if greater; For Reissues, see above	*Reduce	ed by Basic	Filing Fee	e Paid	SUBTOTAL (3) (\$)		
SUBMITTED BY Complete (If applicable)							
SUBMITTED BY Complete (if applicable)							

Name (Print/Type) Mark C. Nelligan, R. g. No. 36,389 36,389 Telephone (908) 231-2388 (Attorney/Agent) September 18, 2003 Date Signature

> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.